Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease

Kidney International

Volumn 90, Issue 1, 2016, Pages 90-99

  Cebotaru, Liudmila ^a   Liu, Qiangni ^b   Yanda, Murali K ^a   Boinot, Clement ^a   Outeda, Patricia ^b   Huso, David L ^a   Watnick, Terry ^b   Guggino, William B ^a   Cebotaru, Valeriu ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

autosomal dominant polycystic kidney disease; cyclic AMP; histone deacetylase 6 inhibitor; renal cyst growth

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; CHLORIDE; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIMETHYL SULFOXIDE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 6 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; POLYCYSTIN 1; TUBACIN; UNCLASSIFIED DRUG; ANILIDE; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE; HYDROXAMIC ACID; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHLORIDE CURRENT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM; EPITHELIUM CELL; FEMALE; IN VITRO STUDY; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; MDCK CELL LINE; MOUSE; MOUSE MODEL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECRETION (PROCESS); ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DOG; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANILIDES; ANIMALS; CELL PROLIFERATION; CHLORIDES; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; DOGS; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TRPP CATION CHANNELS;

EID: 84988345928     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.01.026     Document Type: Article

References (50)

1. 1 Wilson, P.D., Polycystic kidney disease. N Engl J Med 350 (2004), 151–164.
2. 2 Hughes, J., Ward, C.J., Peral, B., et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 10 (1995), 151–160.
3. 3 Mochizuki, T., Wu, G., Hayashi, T., et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272 (1996), 1339–1342.
4. 4 Harris, P.C., Torres, V.E., Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124 (2014), 2315–2324.
5. 5 Torres, V.E., Harris, P.C., Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76 (2009), 149–168.
6. 6 Torres, V.E., Chapman, A.B., Devuyst, O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367 (2012), 2407–2418.
7. 7 Ramasubbu, K., Gretz, N., Bachmann, S., Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 9 (1998), 937–945.
8. 8 Hanaoka, K., Devuyst, O., Schwiebert, E.M., et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 270 (1996), C389–C399.
9. 9 Smith, L.A., Bukanov, N.O., Husson, H., et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17 (2006), 2821–2831.
10. 10 Wang, X., Harris, P.C., Somlo, S., et al. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transpl 24 (2009), 526–534.
11. 11 Starremans, P.G., Li, X., Finnerty, P.E., et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. Kidney Int 73 (2008), 1394–1405.
12. 12 Ye, M., Grant, M., Sharma, M., et al. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 3 (1992), 984–994.
13. 13 Li, Y., Shin, D., Kwon, S.H., Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J 280 (2013), 775–793.
14. 14 Micelli, C., Rastelli, G., Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 20 (2015), 718–735.
15. 15 Li, L., Yang, X.J., Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell Mol Life Sci 72 (2015), 4237–4255.
16. 16 Zhang, Y., Kwon, S., Yamaguchi, T., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28 (2008), 1688–1701.
17. 17 Kalin, J.H., Bergman, J.A., Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem 56 (2013), 6297–6313.
18. 18 Rodriguez-Gonzalez, A., Lin, T., Ikeda, A.K., et al. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 68 (2008), 2557–2560.
19. 19 Sung, Y.M., Lee, T., Yoon, H., et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol 239 (2013), 192–201.
20. 20 de Zoeten, E.F., Wang, L., Butler, K., et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 31 (2011), 2066–2078.
21. 21 Hideshima, T., Bradner, J.E., Wong, J., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102 (2005), 8567–8572.
22. 22 Liu, W., Fan, L.X., Zhou, X., et al. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PloS One, 7, 2012, e49418.
23. 23 Hubbert, C., Guardiola, A., Shao, R., et al. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002), 455–458.
24. 24 Lee, Y.S., Lim, K.H., Guo, X., et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68 (2008), 7561–7569.
25. 25 Nims, N., Vassmer, D., Maser, R.L., Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. Biochemistry 42 (2003), 13035–13048.
26. 26 Lantinga-van Leeuwen, I.S., Dauwerse, J.G., Baelde, H.J., et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13 (2004), 3069–3077.
27. 27 Park, E.Y., Sung, Y.H., Yang, M.H., et al. Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. J Biol Chem 284 (2009), 7214–7222.
28. 28 Thivierge, C., Kurbegovic, A., Couillard, M., et al. Overexpression of PKD1 causes polycystic kidney disease. Mol Cell Biol 26 (2006), 1538–1548.
29. 29 Cebotaru, V., Cebotaru, L., Kim, H., et al. Polycystin-1 negatively regulates polycystin-2 expression via the aggresome/autophagosome pathway. J Biol Chem 289 (2014), 6404–6414.
30. 30 Kawaguchi, Y., Kovacs, J.J., McLaurin, A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003), 727–738.
31. 31 Hwang, T.C., Sheppard, D.N., Molecular pharmacology of the CFTR Cl- channel. Trends Pharmacol Sci 20 (1999), 448–453.
32. 32 Gadsby, D.C., Nairn, A.C., Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 79 (1999), S77–S107.
33. 33 Rapino, D., Sabirzhanova, I., Lopes-Pacheco, M., et al. Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PloS One, 10, 2015, e0119796.
34. 34 Lopes-Pacheco, M., Boinot, C., Sabirzhanova, I., et al. Combination of correctors rescue DeltaF508-CFTR by reducing its association with Hsp 40 and 27. J Biol Chem 290 (2015), 25636–25645.
35. 35 Fan, L.X., Li, X., Magenheimer, B., et al. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81 (2012), 76–85.
36. 36 Cao, Y., Semanchik, N., Lee, S.H., et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci U S A 106 (2009), 21819–21824.
37. 37 Zhou, X., Fan, L.X., Sweeney, W.E. Jr., et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest 123 (2013), 3084–3098.
38. 38 Nadasdy, T., Laszik, Z., Blick, K.E., et al. Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 4 (1994), 2032–2039.
39. 39 Lin, F., Hiesberger, T., Cordes, K., et al. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A 100 (2003), 5286–5291.
40. 40 Pugacheva, E.N., Jablonski, S.A., Hartman, T.R., et al. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 129 (2007), 1351–1363.
41. 41 Cadigan, K.M., Peifer, M., Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol, 1, 2009, a002881.
42. 42 Kim, E., Arnould, T., Sellin, L.K., et al. The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274 (1999), 4947–4953.
43. 43 Song, X., Di Giovanni, V., He, N., et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18 (2009), 2328–2343.
44. 44 Li, Y., Zhang, X., Polakiewicz, R.D., et al. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 283 (2008), 12686–12690.
45. 45 Deribe, Y.L., Wild, P., Chandrashaker, A., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal, 2, 2009, ra84.
46. 46 Tapia, M., Wandosell, F., Garrido, J.J., Impaired function of HDAC6 slows down axonal growth and interferes with axon initial segment development. PloS One, 5, 2010, e12908.
47. 47 Shibazaki, S., Yu, Z., Nishio, S., et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 17 (2008), 1505–1516.
48. 48 Ma, M., Tian, X., Igarashi, P., et al. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 45 (2013), 1004–1012.
49. 49 Piontek, K., Menezes, L.F., Garcia-Gonzalez, M.A., et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13 (2007), 1490–1495.
50. 50 Traykova-Brauch, M., Schonig, K., Greiner, O., et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med 14 (2008), 979–984.